Fate Therapeutics Earnings Calls

Q4 2024 (Upcoming)
Release date Feb 24, 2025
EPS estimate -$0.440
EPS actual -
Revenue estimate 1.466M
Revenue actual -
Expected change +/- 7.26%
Q3 2024 Beat
-$0.400 (4.76%)
Release date Nov 12, 2024
EPS estimate -$0.420
EPS actual -$0.400
EPS Surprise 4.76%
Revenue estimate 1.32M
Revenue actual 3.074M
Revenue Surprise 132.88%
Q2 2024 Beat
-$0.330 (29.79%)
Release date Aug 13, 2024
EPS estimate -$0.470
EPS actual -$0.330
EPS Surprise 29.79%
Revenue estimate 1.41M
Revenue actual 6.772M
Revenue Surprise 380.28%
Q1 2024
Release date May 09, 2024
EPS estimate -$0.470
EPS actual -$0.470
Revenue estimate 1.11M
Revenue actual 1.925M
Revenue Surprise 73.42%

Last 4 Quarters for Fate Therapeutics

Below you can see how FATE performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q1 2024
Release date May 09, 2024
Fiscal end date Mar 31, 2024
Price on release $3.90
EPS estimate -$0.470
EPS actual -$0.470
Date Price
May 03, 2024 $4.06
May 06, 2024 $4.22
May 07, 2024 $3.88
May 08, 2024 $3.70
May 09, 2024 $3.90
May 10, 2024 $4.08
May 13, 2024 $4.15
May 14, 2024 $4.22
May 15, 2024 $4.24
4 days before -3.94%
4 days after 8.72%
On release day 4.62%
Change in period 4.43%
Q2 2024 Beat
Release date Aug 13, 2024
Fiscal end date Jun 30, 2024
Price on release $3.34
EPS estimate -$0.470
EPS actual -$0.330
EPS surprise 29.79%
Date Price
Aug 07, 2024 $3.98
Aug 08, 2024 $3.62
Aug 09, 2024 $3.37
Aug 12, 2024 $3.33
Aug 13, 2024 $3.34
Aug 14, 2024 $3.27
Aug 15, 2024 $3.39
Aug 16, 2024 $3.40
Aug 19, 2024 $3.64
4 days before -16.08%
4 days after 8.98%
On release day -2.10%
Change in period -8.54%
Q3 2024 Beat
Release date Nov 12, 2024
Fiscal end date Sep 30, 2024
Price on release $2.38
EPS estimate -$0.420
EPS actual -$0.400
EPS surprise 4.76%
Date Price
Nov 06, 2024 $2.79
Nov 07, 2024 $2.55
Nov 08, 2024 $2.42
Nov 11, 2024 $2.56
Nov 12, 2024 $2.38
Nov 13, 2024 $2.17
Nov 14, 2024 $2.08
Nov 15, 2024 $2.02
Nov 18, 2024 $2.27
4 days before -14.70%
4 days after -4.62%
On release day -8.82%
Change in period -18.64%
Q4 2024 (Upcoming)
Release date Feb 24, 2025
Fiscal end date Dec 30, 2024
Price on release -
EPS estimate -$0.440
EPS actual -
Date Price
Feb 10, 2025 $1.25
Feb 11, 2025 $1.21
Feb 12, 2025 $1.25
Feb 13, 2025 $1.27
Feb 14, 2025 $1.42

Fate Therapeutics Earnings History

Earnings Calendar

FAQ

When is the earnings report for FATE?
Fate Therapeutics (FATE) has scheduled its earnings report for Feb 24, 2025 before the markets open.

What is the FATE price-to-earnings (P/E) ratio?
FATE P/E ratio as of Feb 14, 2025 (TTM) is -0.83.

What is the FATE EPS forecast?
The forecasted EPS (Earnings Per Share) for Fate Therapeutics (FATE) for the first fiscal quarter 2024 is -$0.440.

What are Fate Therapeutics's retained earnings?
On its balance sheet, Fate Therapeutics reported retained earnings of $3.07 million for the latest quarter ending Sep 30, 2024.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT FATE THERAPEUTICS
Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat mul...
GOLDEN STAR
Ticker Change Signal Date
T
TBIL
$49.90
0.0802% Feb 12
I
IBTF
$23.33
0.0429% Feb 12
SKT
$33.58
2.00% Feb 12
BSY
$46.63
1.33% Feb 11
IBN
$29.02
0.482% Feb 11

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE